• Hilary J Longhurst, Werner Aberer, Laurence Bouillet, Teresa Caballero, Marcus Maurer, Vincent Fabien, Andrea Zanichelli, and IOS Study Group.
• aDepartment of Immunology, Barts Health NHS TrustbDepartment of Dermatology and Venereology, Medical University of Graz, Graz, AustriacInternal Medicine Department, National Reference Centre for Angioedema, Grenoble University Hospital, Grenoble, FrancedAllergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, SpaineDepartment of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, GermanyfShire, Zug, SwitzerlandgDepartment of Biomedical and Clinical Sciences, University of Milan, Luigi Sacco Hospital, Milan, Italy.
• Eur J Emerg Med. 2016 Jun 1; 23 (3): 224-7.

ObjectiveTo characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry.MethodsThis retrospective analysis was based on data from patients with HAE type I/II who received healthcare professional-administered or self-administered icatibant to treat laryngeal attacks between September 2008 and May 2013.ResultsTwenty centers in seven countries contributed data. Overall, 42 patients with HAE experienced 67 icatibant-treated laryngeal attacks. Icatibant was self-administered for 62.3% of attacks (healthcare professional-administered, 37.7%). One icatibant injection was used for 87.9% of attacks, with rescue or concomitant medication used for 9.0%. The median time to treatment was 2.0 h (n=31 attacks) and the median time to resolution was 6.0 h (n=35 attacks).ConclusionsThis analysis describes successful use of icatibant for the treatment of laryngeal HAE attacks in a real-world setting.

31 keywords...

hide…